Our Mission

Alleviate the symptoms of type 2 diabetes for patients worldwide with a pioneering, reversible implant.

 

Product Overview
EndoBarrier treatment for diabetes & obesity

Proven Results for Type 2 Diabetes & Obesity

In two separate studies, 80% of patients maintained their achieved weight loss eight months’ post-EndoBarrier removal and 77% maintained it for 12 months or more.

 

BBC News Video
Endobarrier treatment for diabetes & obesity following 1 year results of ABCD study

Pioneering and Simply Effective.

EndoBarrier is the first Type 2 Diabetes and Obesity treatment of its kind: reversible, no surgery and proven benefits.

 

ABCD EndoBarrier Study
1-year results, including 10-year CV Risk assessment – Robert Ryder, MD, 2016

Conquer the World's Biggest Epidemics.
Join Us.

Investor confidence and invigorated leadership are combining to bring EndoBarrier to the US.

The Need by the Numbers

The Treatment Gap

Minimally Invasive Procedure Fills the “Treatment Gap”

  • Aids in the treatment of Type 2 Diabetes and Obesity
  • Minimal Risk
  • Cost-Effective

Videos

GID in the News

9/24

IK+EM Study Released at EASD Shows Similar Outcomes Between Gastric Plication and EndoBarrier

LISBON, PORTUGAL — 25 September 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier®...
8/22

GI Dynamics Appoints Juliet Thompson to Company’s Board of Directors

BOSTON and SYDNEY— 23 August 2017— GI Dynamics® Inc. (ASX:GID), a medical device company that commercialized EndoBarrier® in Europe,...
8/13

GI Dynamics Welcomes New Members to Its Scientific Advisory Board

BOSTON and SYDNEY — 14 August 2017 — GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized...
8/9

GI Dynamics to Provide Shareholder Update on 2017 Second Quarter Results

BOSTON and SYDNEY – 10 August 2017 – GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier®...